ScreenerHero

ANRO Alto Neuroscience, Inc.

NYSE · US · Healthcare · Biotechnology · altoneuroscience.com
23.52USD-0.72%Mkt Cap: 922.97M $P/E: —

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients wit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap922.97M USD
Enterprise Value709.21M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.24M USD
Revenue/Share—
Last Price23.52 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.21
PEG—
EV/EBITDA-8.10
EV/Revenue—
P/S—
P/B3.79
EPS (TTM)-2.31
EPS (Forward)-3.29
52W Range
3.77059% of range37.43
52W High37.43 USD
52W Low3.770 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.84%
ROA-34.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.77M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-4.65%
Net Debt-220.44M USD
Net Debt/EBITDA2.52
Balance Sheet
Debt/Equity0.16
Current Ratio14.85
Quick Ratio14.64
Book Value/Sh6.25 USD
Cash/Share6.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.38 USD
Upside (mean)+63.2%
Target Range26.00 USD – 55.00 USD
26.00+63.2% to mean55.00
# Analysts10
Ownership
Shares Out.39.24M
Float29.65M
Insiders4.07%
Institutions87.10%
Short Interest
Short Ratio8.9d
Short % Float12.46%
Short % Out.10.64%
Shares Short4.17M
Short (prev mo.)3.56M
Technical
SMA 5030.84 (-23.7%)
SMA 20023.75 (-1.0%)
Beta1.34
S&P 52W Chg16.45%
Avg Vol (30d)559.82K
Avg Vol (10d)617.05K
Technical Indicators
RSI (14)22.6
MACD-2.1469
MACD Signal-1.5970
MACD Hist.-0.5500
BB Upper33.89 USD
BB Middle27.98 USD
BB Lower22.07 USD
BB Width42.26%
ATR (14)1.778 USD
Vol Ratio (20d)0.54x